This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Comments
Loading...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc CPRX with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. See how other analysts view this stock.
  • Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation EXE with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. See how other analysts view this stock.
  • BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation TRNO with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. See how other analysts view this stock.
  • Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. VERA with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. See how other analysts view this stock.
  • Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. ORKA with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. See how other analysts view this stock.

Considering buying EXE stock? Here’s what analysts think:

CPRX Logo
CPRXCatalyst Pharmaceuticals Inc
$21.952.58%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
92.85
Growth
-
Quality
90.28
Value
53.04
Price Trend
Short
Medium
Long
Got Questions? Ask
How will Catalyst Pharmaceuticals perform with upgrades?
What factors drive Expand Energy's bullish outlook?
Which investors are targeting Terreno Realty now?
Could Vera Therapeutics see stock price increases?
What market trends affect Oruka Therapeutics growth?
How will analyst ratings impact biotech stocks?
What does the real estate sector predict for TRNO?
Will energy investments shift after EXE's rating?
Which therapeutics companies might follow suit?
Can analyst upgrades influence overall market sentiment?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In: